ArticleWorld journal of urology2025
Safety and feasibility of prone retroperitoneal robotic-assisted partial nephrectomy (prRAPN): a novel posterior approach and perioperative results - a prospective study.
Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prone retroperitoneal versus lateral retroperitoneal robotic assisted partial nephrectomy: a propensity score-matched comparison.World journal of urology · 2026Article
- Prone retroperitoneal robotic-assisted laparoscopic pyeloplasty for ureteropelvic junction obstruction.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeLateral positioning remains standard for retroperitoneal robotic-assisted partial nephrectomy (rRAPN). Emerging single-port systems have expanded supine positioning applications in rRAPN. This study evaluates the feasibility and safety of novel prone retroperitoneal RAPN (prRAPN).
methodsFrom August 2023 to December 2024, 108 patients with renal tumors in various anatomical locations prospectively underwent prRAPN. Demographic and perioperative parameters were analyzed.
resultsThis prospective cohort (n = 108) demonstrated median age 59 years, BMI 24.6 kg/m², R.E.N.A.L. score 7, and PADUA score 9. 10 patients had stage ≥ 3 chronic kidney disease, 75 had an age-adjusted charlson comorbidity index ≥ 2 and 23 had an American Society of Anesthesiologists score ≥ 3. All 86 patients with renal malignancies achieved negative surgical margins. Operative outcomes demonstrated median hilar access time 5.3 min, warm ischemia time 20.3 min, operation time 47.3 min, and estimated blood loss 50 mL. Postoperative 90-day ΔeGFR decreased by 7.2 mL/(min·1.73m
conclusionsPreliminary results demonstrated prRAPN is feasible and safe, which could expedite access to surgical area and improve exposure of posterior tumor. Larger-scale and multi-center studies are needed for confirmation.
Indexed as
Identifiers
40531237What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.